Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Nina, Dedic"'
Autor:
Jakob Hartmann, Thomas Bajaj, Joy Otten, Claudia Klengel, Tim Ebert, Anne-Kathrin Gellner, Ellen Junglas, Kathrin Hafner, Elmira A. Anderzhanova, Fiona Tang, Galen Missig, Lindsay Rexrode, Daniel T. Trussell, Katelyn X. Li, Max L. Pöhlmann, Sarah Mackert, Thomas M. Geiger, Daniel E. Heinz, Roy Lardenoije, Nina Dedic, Kenneth M. McCullough, Tomasz Próchnicki, Thomas Rhomberg, Silvia Martinelli, Antony Payton, Andrew C. Robinson, Valentin Stein, Eicke Latz, William A. Carlezon, Felix Hausch, Mathias V. Schmidt, Chris Murgatroyd, Sabina Berretta, Torsten Klengel, Harry Pantazopoulos, Kerry J. Ressler, Nils C. Gassen
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-20 (2024)
Abstract High levels of proinflammatory cytokines induce neurotoxicity and catalyze inflammation-driven neurodegeneration, but the specific release mechanisms from microglia remain elusive. Here we show that secretory autophagy (SA), a non-lytic moda
Externí odkaz:
https://doaj.org/article/83209dbad20940cdab3e3f6f4104353f
Autor:
Nina Dedic, Lien Wang, Eva Hajos-Korcsok, Jacob Hecksher-Sørensen, Urmas Roostalu, Steven P. Vickers, Serena Wu, Christoph Anacker, Colleen Synan, Philip G. Jones, Snezana Milanovic, Seth C. Hopkins, Linda J. Bristow, Kenneth S. Koblan
Publikováno v:
Molecular Metabolism, Vol 80, Iss , Pp 101883- (2024)
Objective: Metabolic Syndrome, which can be induced or exacerbated by current antipsychotic drugs (APDs), is highly prevalent in schizophrenia patients. Recent preclinical and clinical evidence suggest that agonists at trace amine-associated receptor
Externí odkaz:
https://doaj.org/article/b7fe5a8971f046fa9b051d0ee080c127
Publikováno v:
Translational Psychiatry, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract SEP-363856 is a trace amine-associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5-HT1A) agonist, currently in Phase 3 clinical trials for the treatment of schizophrenia. Although SEP-363856 activates TAAR1 and 5-HT1A receptors in
Externí odkaz:
https://doaj.org/article/dd0a23c2a1284660abbf9f68fe67166d
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 24, p 13185 (2021)
Trace amine-associated receptor 1 (TAAR1) has emerged as a promising therapeutic target for neuropsychiatric disorders due to its ability to modulate monoaminergic and glutamatergic neurotransmission. In particular, agonist compounds have generated i
Externí odkaz:
https://doaj.org/article/24a2a645c47f4a17ae96659ce4bf3218
Publikováno v:
European Archives of Psychiatry and Clinical Neuroscience.
Ulotaront is a trace amine-associated receptor 1 (TAAR1) agonist in Phase 3 clinical development for the treatment of schizophrenia. Ulotaront was discovered through a unique, target-agnostic approach optimized to identify drug candidates lacking D2
Autor:
Nina Dedic, Claudia Kühne, Karina S. Gomes, Jakob Hartmann, Kerry J. Ressler, Mathias V. Schmidt, Jan M. Deussing
Publikováno v:
Frontiers in Neuroscience, Vol 13 (2019)
Dysregulation of the corticotropin-releasing hormone (CRH) system has been implicated in stress-related psychopathologies such as depression and anxiety. Although most studies have linked CRH/CRH receptor 1 signaling to aversive, stress-like behavior
Externí odkaz:
https://doaj.org/article/d997b72259724e658687c6540d4c1c3c
Autor:
Jakob Hartmann, Thomas Bajaj, Joy Otten, Claudia Klengel, Anne-Kathrin Gellner, Ellen Junglas, Kathrin Hafner, Elmira A Anderzhanova, Fiona Tang, Galen Missig, Lindsay Rexrode, Katelyn Li, Max L Pöhlmann, Daniel E Heinz, Roy Lardenoije, Nina Dedic, Kenneth M McCullough, Tomasz Próchnicki, Thomas Rhomberg, Silvia Martinelli, Antony Payton, Andrew C. Robinson, Valentin Stein, Eicke Latz, William A Carlezon, Mathias V Schmidt, Chris Murgatroyd, Sabina Berretta, Torsten Klengel, Harry Pantazopoulos, Kerry J Ressler, Nils C Gassen
Publikováno v:
bioRxiv
SummaryHigh levels of proinflammatory cytokines induce neurotoxicity and catalyze inflammation-driven neurodegeneration, but the specific release mechanisms from microglia remain elusive. We demonstrate that secretory autophagy (SA), a non-lytic moda
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3ecd45553917cdd990d78b46f7a9099
https://europepmc.org/articles/PMC10103985/
https://europepmc.org/articles/PMC10103985/
Autor:
Guangqing Xiao, Yu-Luan Chen, Nina Dedic, Linghong Xie, Kenneth S. Koblan, Gerald R. Galluppi
Publikováno v:
Pharmaceutical Research. 39:837-850
Purpose Ulotaront (SEP-363856) is a TAAR1 agonist with 5-HT1A agonist activity currently in clinical development for the treatment of schizophrenia. The objectives of the current study were to characterize the in vitro ADME properties, preclinical PK
Publikováno v:
CNS Spectrums. 28:221-221
IntroductionTrace amine-associated receptors (TAARs) are a family of G-protein-coupled receptors (GPCRs) first identified in 2001. TAAR1 has emerged as a promising therapeutic target due to its ability to modulate monoaminergic and glutamatergic neur
Autor:
Nina Dedic, Philip G. Jones, Eva Hajos-Korcsok, Colleen Synan, Serena Wu, Christoph Anacker, Steve P. Vickers, Jacob Hecksher-Sørensen, Courtney Zeni, Snezana Milanovic, Seth C. Hopkins, Linda J. Bristow, Kenneth S. Koblan
Publikováno v:
CNS Spectrums. 28:259-259
IntroductionPreclinical evidence has identified the trace amine-associated receptor 1 (TAAR1) as a novel regulator of metabolic control. Ulotaront is a TAAR1 and 5-HT1A agonist currently in Phase 3 clinical trials for the treatment of schizophrenia.